Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Hepatitis B Virus Vertical Transmission by Serovaccination and Tenofovir During Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women~* positive for HBs Ag~* HBV DNA above 100,000 I.U/mL~Exclusion Criteria:~* HIV co-infection~* HDV co-infection~* requiring, according to the physician's decision, a treatment for herself and not only to prevent HBV MTC transmission

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tenofovir (Type: OTHER): tenofovir DF one pill (245 mg) per day from week 28 of pregnancy to week 12 after birth

Based on this trial design, predict the completion outcome and termination type (if applicable).